TY - JOUR
T1 - Evidence-based treatments for couples with unexplained infertility
T2 - a guideline
AU - Practice Committee of the American Society for Reproductive Medicine
AU - Penzias, Alan
AU - Bendikson, Kristin
AU - Falcone, Tommaso
AU - Hansen, Karl
AU - Hill, Micah
AU - Jindal, Sangita
AU - Mersereau, Jennifer
AU - Racowsky, Catherine
AU - Rebar, Robert
AU - Steiner, Anne Z.
AU - Stovall, Dale
AU - Tanrikut, Cigdem
AU - Kalra, Suleena
AU - Reindollar, Richard
AU - Hurd, William
N1 - Funding Information:
The Practice Committee acknowledges the special contributions of Karl Hansen, MD, PhD (Chair); Karine Chung, MD; Jessica Goldstein, RN; Jennifer Hirshfeld-Cytron, MD; Zac Knight, PhD; Daniel Lebovic, MD; Paul Lin, MD; Richard Lucidi, MD; Carla Stec, MA, in the development of this document. No relevant conflicts were identified. Following are members of the ASRM Practice Committee who participated in the development and review of this document:, Alan Penzias, M.D. (Chair); Kristin Bendikson, M.D.; Tommaso Falcone, M.D.; Karl Hansen, M.D. Ph.D.; Micah Hill, D.O.; Sangita Jindal, Ph.D.; Jennifer Mersereau, M.D.; Catherine Racowsky, Ph.D.; Robert Rebar, M.D.; Anne Z. Steiner, M.D. M.P.H.; Dale Stovall, M.D.; Cigdem Tanrikut, M.D.; Suleena Kalra, M.D. M.S.C.E.; Richard Reindollar, M.D.; William Hurd, M.D. M.P.H.
Funding Information:
This guideline was developed with financial support from the American Society for Reproductive Medicine (ASRM). Authors who serve on the ASRM Practice Committee were reimbursed by ASRM for expenses related to travel to Practice Committee meetings where they reviewed drafts of manuscripts. ASRM receives no outside funding for the development of guidelines.
Publisher Copyright:
© 2019 American Society for Reproductive Medicine
PY - 2020/2
Y1 - 2020/2
N2 - Objective: To provide evidence-based recommendations to practicing physicians and others regarding the effectiveness and safety of therapies for unexplained infertility. Methods: ASRM conducted a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 1968 through 2019. The ASRM Practice Committee and a task force of experts used available evidence and informal consensus to develop evidence-based guideline recommendations. Main Outcome Measure(s): Outcomes of interest included: live-birth rate, clinical pregnancy rate, implantation rate, fertilization rate, multiple pregnancy rate, dose of treatment, rate of ovarian hyperstimulation, abortion rate, and ectopic pregnancy rate. Result(s): The literature search identified 88 relevant studies to inform the evidence base for this guideline. Recommendation(s): Evidence-based recommendations were developed for the following treatments for couples with unexplained infertility: natural cycle with intrauterine insemination (IUI); clomiphene citrate with intercourse; aromatase inhibitors with intercourse; gonadotropins with intercourse; clomiphene citrate with IUI; aromatase inhibitors with IUI; combination of clomiphene citrate or letrozole and gonadotropins (low dose and conventional dose) with IUI; low-dose gonadotropins with IUI; conventional-dose gonadotropins with IUI; timing of IUI; and in vitro fertilization and treatment paradigms. Conclusion(s): The treatment of unexplained infertility is by necessity empiric. For most couples, the best initial therapy is a course (typically 3 or 4 cycles) of ovarian stimulation with oral medications and intrauterine insemination (OS-IUI) followed by in vitro fertilization for those unsuccessful with OS-IUI treatments.
AB - Objective: To provide evidence-based recommendations to practicing physicians and others regarding the effectiveness and safety of therapies for unexplained infertility. Methods: ASRM conducted a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 1968 through 2019. The ASRM Practice Committee and a task force of experts used available evidence and informal consensus to develop evidence-based guideline recommendations. Main Outcome Measure(s): Outcomes of interest included: live-birth rate, clinical pregnancy rate, implantation rate, fertilization rate, multiple pregnancy rate, dose of treatment, rate of ovarian hyperstimulation, abortion rate, and ectopic pregnancy rate. Result(s): The literature search identified 88 relevant studies to inform the evidence base for this guideline. Recommendation(s): Evidence-based recommendations were developed for the following treatments for couples with unexplained infertility: natural cycle with intrauterine insemination (IUI); clomiphene citrate with intercourse; aromatase inhibitors with intercourse; gonadotropins with intercourse; clomiphene citrate with IUI; aromatase inhibitors with IUI; combination of clomiphene citrate or letrozole and gonadotropins (low dose and conventional dose) with IUI; low-dose gonadotropins with IUI; conventional-dose gonadotropins with IUI; timing of IUI; and in vitro fertilization and treatment paradigms. Conclusion(s): The treatment of unexplained infertility is by necessity empiric. For most couples, the best initial therapy is a course (typically 3 or 4 cycles) of ovarian stimulation with oral medications and intrauterine insemination (OS-IUI) followed by in vitro fertilization for those unsuccessful with OS-IUI treatments.
KW - Unexplained infertility
KW - in vitro fertilization
KW - intrauterine insemination
KW - multiple pregnancy
KW - ovarian stimulation
UR - http://www.scopus.com/inward/record.url?scp=85079908679&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079908679&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2019.10.014
DO - 10.1016/j.fertnstert.2019.10.014
M3 - Article
C2 - 32106976
AN - SCOPUS:85079908679
SN - 0015-0282
VL - 113
SP - 305
EP - 322
JO - Fertility and sterility
JF - Fertility and sterility
IS - 2
ER -